Brainsway Ltd. BWAY
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BrainsWay Ltd. is an Israel-based medical device company focused on noninvasive neurostimulation therapies for mental health and neurological disorders. The company develops and commercializes transcranial magnetic stimulation (TMS) systems using its proprietary Deep TMS technology, which is designed to stimulate broader and deeper regions of the brain than conventional TMS approaches. BrainsWay operates primarily within the medical technology, mental health treatment, and neuropsychiatric device industries. Its revenue is primarily generated through sales and leasing of Deep TMS systems, treatment coils, and recurring service and support arrangements for healthcare providers and psychiatric clinics.
The company’s flagship platform, the Deep TMS System, has received multiple regulatory clearances and approvals, including U.S. Food and Drug Administration clearances for treatment-resistant major depressive disorder, obsessive-compulsive disorder, smoking addiction, and anxious depression indications. BrainsWay serves psychiatric practices, hospitals, addiction treatment centers, and healthcare networks, with a strategic focus on expanding adoption of neurostimulation therapies as alternatives or complements to pharmaceutical treatments. Founded in 2003 and headquartered in Jerusalem, the company evolved from early neuroscience research into a publicly traded medical technology company listed on Nasdaq under the ticker BWAY.
Business Operations
BrainsWay organizes its operations primarily around commercialization of its Deep TMS neurostimulation platform and related treatment accessories. The company generates revenue from capital equipment sales, recurring coil and consumable usage, maintenance agreements, and leasing arrangements with healthcare providers. Its core technology portfolio includes proprietary H-Coil designs intended for specific psychiatric and neurological indications. The company maintains intellectual property related to magnetic stimulation hardware, coil architecture, and treatment protocols.
The company operates commercially across the United States, Europe, Israel, and selected international markets through direct sales teams and distribution partnerships. The United States represents its largest commercial market based on public filings and investor disclosures. BrainsWay has collaborated with healthcare providers, research institutions, and clinical centers to support clinical validation and market expansion. The company also works with reimbursement stakeholders and insurers to improve patient access to TMS therapies. Public disclosures identify ongoing investments in clinical studies and regulatory pathways intended to broaden approved indications and increase utilization of its platform.
Strategic Position & Investments
BrainsWay’s strategic direction centers on expanding the clinical adoption of Deep TMS technology across additional neuropsychiatric and neurological indications. The company has invested in clinical research aimed at supporting new regulatory approvals and reimbursement coverage, particularly in areas such as depression, obsessive-compulsive disorder, addiction, and other mental health conditions. Management has emphasized recurring revenue growth through increased utilization of installed systems and expansion of treatment centers using its technology.
The company’s competitive positioning is based largely on its proprietary Deep TMS coil technology, existing FDA-cleared indications, and clinical data portfolio. BrainsWay has also pursued strategic collaborations with healthcare systems and research organizations to strengthen market credibility and physician adoption. Publicly available filings and investor materials indicate continued investment in product development, commercialization infrastructure, and international expansion initiatives. Data regarding significant minority investments or extensive portfolio holdings is limited in public disclosures, and no large-scale acquisition program comparable to major diversified medical device companies has been prominently identified.
Geographic Footprint
BrainsWay is headquartered in Jerusalem, Israel, with significant commercial operations concentrated in the United States, which serves as its primary revenue-generating market. The company markets its Deep TMS systems across North America, parts of Europe, Asia-Pacific, and selected additional international territories through a combination of direct operations and third-party distributors. Regulatory clearances in multiple jurisdictions have supported broader international commercialization efforts.
The company’s operational footprint includes sales, clinical support, and distribution activities targeting psychiatric clinics, hospitals, and mental health providers in developed healthcare markets. Public filings indicate strategic emphasis on expanding reimbursement-supported treatment adoption in the United States while selectively increasing international penetration. BrainsWay’s global presence remains focused primarily on specialized neuropsychiatric treatment markets rather than broad consumer healthcare distribution.
Leadership & Governance
BrainsWay is governed by a board of directors and executive leadership team with backgrounds in medical technology, healthcare commercialization, neuroscience, and finance. The company’s leadership strategy has focused on expanding clinical adoption of Deep TMS therapy, strengthening reimbursement access, and increasing recurring revenue from installed systems. Corporate governance practices are disclosed through SEC filings, annual reports, and Nasdaq compliance documentation.
Key executives identified in recent public filings and company disclosures include:
- Hadar Levy – Interim Chief Executive Officer
- Ronen Pipano – Chief Financial Officer
- Dr. Yiftach Roth – Chief Medical Officer
- Eyal Ben-Ami – Chief Operating Officer
BrainsWay was founded by researchers and entrepreneurs associated with developments in neurostimulation technology and has maintained a research-driven strategic orientation since inception. Leadership communications in investor presentations and regulatory filings consistently emphasize evidence-based treatment expansion, clinical validation, and commercialization discipline within the neuropsychiatric device market.